Immune Cell Therapy Protocol – Definition & Process
An immune cell therapy protocol is a structured treatment plan for cell-based immunotherapies, e.g. in cancer care. It defines dosing, procedures, and patient monitoring.
Things worth knowing about "Immune Cell Therapy Protocol"
An immune cell therapy protocol is a structured treatment plan for cell-based immunotherapies, e.g. in cancer care. It defines dosing, procedures, and patient monitoring.
What Is an Immune Cell Therapy Protocol?
An immune cell therapy protocol is a standardized medical treatment plan that outlines all relevant steps of a cell-based immunotherapy. It covers the collection, processing, administration, and follow-up care of immune cells used to treat diseases – most notably cancer, autoimmune conditions, or severe infections. The protocol serves as a binding guideline for healthcare professionals, ensuring a safe, reproducible, and effective therapy.
Types of Immune Cell Therapy
Immune cell therapies use the patient's own or donor-derived immune cells that are specifically modified or activated to fight pathogens or tumor cells. The main forms include:
- CAR T-cell therapy: The patient's T-cells are genetically engineered with a chimeric antigen receptor (CAR) to recognize and destroy tumor cells.
- Natural killer cell therapy (NK-cell therapy): NK cells are isolated, expanded, and activated to attack tumor cells or virus-infected cells.
- Dendritic cell therapy: Dendritic cells are loaded with tumor-specific antigens to sensitize the immune system against cancer cells.
- TIL therapy (tumor-infiltrating lymphocytes): Lymphocytes from the patient's tumor tissue are extracted, expanded in the laboratory, and reinfused.
- Allogeneic stem cell transplantation: Immune cells from a healthy donor are transferred to rebuild the patient's immune system.
Structure of an Immune Cell Therapy Protocol
A complete protocol is typically divided into several phases:
1. Patient Selection and Pre-Treatment Assessments
The patient's suitability and health status are thoroughly evaluated. This includes complete blood counts, immunological tests, imaging procedures, and detailed disease characterization (e.g., tumor markers, genetic profiles).
2. Cell Collection (Apheresis or Biopsy)
Depending on the therapy type, immune cells are collected via leukapheresis (filtering white blood cells from the bloodstream) or through a tissue biopsy. This step is performed under sterile conditions at specialized centers.
3. Cell Processing and Modification in the Laboratory
The collected cells are purified, expanded, and – if required – genetically modified in a GMP (Good Manufacturing Practice) laboratory. Quality controls ensure the purity, viability, and potency of the cell product before it is administered to the patient.
4. Conditioning Therapy (Preparing the Patient)
Prior to cell infusion, patients typically receive a lymphodepleting preconditioning regimen (usually chemotherapy) to suppress the existing immune system and create space for the infused cells to expand and engraft.
5. Cell Infusion
The processed immune cells are administered intravenously. The infusion is performed under close medical supervision, as immediate reactions are possible.
6. Monitoring and Follow-Up Care
After infusion, the patient is closely monitored for early detection of adverse events. Particularly relevant complications include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Regular follow-up assessments (blood tests, imaging) document the treatment response.
Indications
Immune cell therapy protocols are primarily used in the following areas:
- Hematologic malignancies (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma)
- Solid tumors (under clinical investigation)
- Severe autoimmune diseases
- Chronic viral infections (e.g., HIV, CMV after transplantation)
Side Effects and Risks
Like any intensive treatment, immune cell therapy carries risks. The most common and clinically significant side effects include:
- Cytokine release syndrome (CRS): A systemic inflammatory response with fever, low blood pressure, and potential organ damage
- ICANS: Neurological symptoms such as confusion, speech impairment, or seizures
- Infections: Increased infection risk due to a weakened immune system
- Cytopenias: Reduction in blood and immune cell counts
- Tumor lysis syndrome: Metabolic imbalance caused by the rapid breakdown of large numbers of tumor cells
Regulatory Requirements
Immune cell therapies are classified in the European Union as Advanced Therapy Medicinal Products (ATMPs) and are subject to strict authorization and quality requirements set by the European Medicines Agency (EMA). The manufacturing of cell products must comply with GMP standards, and clinical protocols must be ethically reviewed and officially approved.
References
- European Medicines Agency (EMA): Guideline on human cell-based medicinal products. EMA/CHMP/410869/2008. Available at: https://www.ema.europa.eu
- June CH, Sadelain M. Chimeric Antigen Receptor Therapy. New England Journal of Medicine. 2018;379(1):64-73.
- Neelapu SS et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine. 2017;377(26):2531-2544.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryIntervention
Regression
Hydrolysate
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Immune Cell Therapy Protocol-en